Cerus (NASDAQ:CERS) Releases Quarterly Earnings Results, Meets Expectations

Cerus (NASDAQ:CERS) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01), Zacks reports. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%.

Cerus Trading Down 3.9 %

Shares of CERS stock traded down $0.07 during trading hours on Thursday, reaching $1.74. The company had a trading volume of 1,189,219 shares, compared to its average volume of 1,460,745. Cerus has a 1-year low of $1.38 and a 1-year high of $2.59. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The firm has a market cap of $323.14 million, a price-to-earnings ratio of -15.82 and a beta of 1.29. The company has a 50 day moving average of $1.74 and a 200 day moving average of $1.84.

Insider Activity at Cerus

In related news, Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the sale, the director now owns 162,133 shares of the company’s stock, valued at approximately $288,596.74. This trade represents a 10.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 3.40% of the stock is currently owned by corporate insiders.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.